Of the 427 patients who received either AAML1031 or AAML0531 were for evaluable response, the total CR of the whole CBF-AML pediatric patients were 95.2%, and 94% with inv(16) and 95.9% with t(8; 21) achieved a CR (P = 0.441), respectively (Table 3). This evidence concerns the gene CEBPZ and acute myeloid leukemia.